Genital human papillomaviruses - prospects for vaccination

Current Opinion in Infectious Diseases

Volumn 10, Issue 1, 1997, Pages 55-61

  Stanley, Margaret ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

CELLULAR IMMUNITY; CONDYLOMA; HUMAN; HUMORAL IMMUNITY; IMMUNOTHERAPY; NONHUMAN; REVIEW; SEROEPIDEMIOLOGY; VERTICAL TRANSMISSION; VIRUS PARTICLE;

EID: 0030944096     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199702000-00013     Document Type: Review

References (64)

1. PHLS Communicable Disease Centre: Sexually transmitted disease in Britain 1985-86. Genitourin Med 1989, 65:117-121.
2. IARC Monographs on the Evaluation of Carcinogen Risks to Humans. Vol. 64, Human papillomaviruses. Lyon, France: World Health Organization International Agency for Research on Cancer, 1995 (Meeting of IARC Working Group on 6-13 June 1995).
3. Coleman N, Birley HD, Renton AM, Hanna NF, Ryait BK, Byrne M, Taylor Robinson D, Stanley MA: Immunological events in regressing genital warts. Am J Clin Pathol 1994, 102:768-774.
4. Nindl I, Zahm DM, Meijer CJLM, Walboomers JMM, Schneider A: Human papillomavirus detection in high-grade squamous epithelial lesions:Comparison of hybrid capture assay with a polymerase chain reaction system. Diagn Microbiol Infect Dis 1995, 23:161-164.
5. Steele JC, Gallimore PH: Humoral assays of human sera to disrupted and nondisrupted epitopes of human papillomavirus type 1. Virology 1990, 174:388-398.
6. Christensen ND, Kreider JW: Antibody mediated neutralization in vivo of infectious papillomaviruses. J Virol 1990, 64:3151-3156.
7. Bonnez W, Da Rin C, Rose RC, Reichman RC: Use of human papillomavirus type 11 virions in an ELISA to detect specific antibodies in humans with condylomata acuminata. J Gen Virol 1991, 72:1343-1347.
8. Christensen ND, Kreider JW, Shah KV, Rando RF: Detection of human serum antibodies that neutralize infectious human papillomavirus type 11 virions. J Gen Virol 1992, 73:1261-1267
9. Zhou J, Sun XY, Stenzel DJ, Frazer IH: Expression of vaccinia recombinant HPV16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991, 185:251-257.
10. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT: Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992, 89:12180-12184.
11. Heino P, Dillner J, Schwartz S: Human papillomavirus type 16 capsid proteins produced from recombinant Semliki Forest virus assemble into virus-like particles. Virology 1995, 214:349-359.
12. Hofmann KJ, Cook JC, Joyce JG, Brown DR, Schultz LD, George HA, Rosolowsky M, Fife KH, Jansen KU: Sequence determination of human papillomavirus type 6a and assembly of virus like particles in Saccharomyces cerevisiae. Virology 1995, 209:506-518.
13. Sasagawa T, Inoue M, Lehtinen M, Zhang W, Geschmeissner SE, Hajipagheri MAN, Finch J, Crawford L: Serological responses to human papillomavirus type 6 and 16 virus like particles in patients with cervical neoplastic lesions. Clin Diagn Lab Immunol 1996, 3:403-410.
14. Hagensee ME, Olson NH, Baker TS, Galloway DA: Three dimensional structure of vaccinia virus produced human papillomavirus type 1 capsids. J Virol 1994, 68:4503-4505.
15. Carter JJ, Wipf GC, Hagensee ME, McKnight B, Habel LA, Lee SK, Kuypers J, Kiviat N, Daling JR, Koutsky LA et al.: Use of human papillomavirus type 6 capsids to detect antibodies in people with genital warts. J Infect Dis 1995, 172:11-18.
16. Heim K, Christensen ND, Hoepfl R, Wartusch B, Pinzger G, Zeimet A, Baumgartner P, Kreider JW, Dapunt O: Serum IgG, IgM, and IgA reactivity to human papillomavirus types 11 and 6 virus like particles in different gynecologic patient groups. J Infect Dis 1995, 172:395-402.
17. Eisemann C, Fisher SG, Gross G, Muller M, Gissmann L: Antibodies to human papillomavirus type 11 particles in sera of patients with genital warts and in control groups. J Gen Virol 1996, 77:1799-1803.
18. Greer CE, Wheeler CM, Ladner MB, Beutner K, Coyne MY, Liang H, Langenberg A, Yen TSB, Ralston R: Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol 1995, 33:2058-2063.
19. Wikstrom A, Van Doornum GJ, Kirnbauer R, Quint WG, Dillner J: Prospective study on the development of antibodies against human papillomavirus type 6 among patients with condyloma acuminata or new asymptomatic infection. J Med Virol 1995, 46:368-374.
20. Wikstrom A, Van Doornum GJ, Quint WG, Schiller JT, Dillner J: Identification of human papillomavirus seroconversions. J Gen Virol 1995, 76:529-539.
21. Andersson-Ellstrom A, Dillner J, Hagmar B, Schiller JT, Sapp M, Forssman L, Milsom I: Comparison of development of serum antibodies to HPV16 and HPV33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls. Sex Transm Dis 1996 (In press).
22. Wideroff L, Schiffman MH, Nonnenmacher B, Hubbert N, Kirnbauer R, Greer CE, Lowy D, Lorincz AT, Manos MM, Glass AG et al.: Evaluation of seroreactivity to human papillomavirus type 16 virus like particles in an incident case control study of cervical neoplasia. J Infect Dis 1995, 172:1425-1430.
23. Nonnenmacher B, Hubbert NL, Kirnbauer R, Shah KV, Munoz N, Bosch FX, De Sanjose S, Viscidi R, Lowy DR, Schiller JT: Serologic response to human papillomavirus type 16 (HPV16) virus like particles in HPV16 DNA positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain. J Infect Dis 1995, 172:19-24.
24. Lehtinen M, Dillner J, Knekt P, Luostarinen T, Aromaa A, Kirnbauer R, Koskela P, Paavonen J, Peto R, Schiller JT et al.: Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case control study [see comments]. BMJ 1996, 312:537-539. A large 23-year prospective study providing epidemiological evidence that infection with HPV16, as determined by antibodies to HPV16 capsid proteins, confers an excess risk for the development of cervical cancer.
25. Cason J, Kaye JN, Jewers RJ, Kambo PK, Bible JM, Kell B, Shergill B, Pakaria NF, Raju KS, Best JM: Perinatal infection and persistence of human papillomavirus types 16 and 18 in infants. J Med Virol 1995, 47:209-218.
26. Puranen M, Yliskoski M, Saarikoski S, Syrjanen K, Syrjanen S: Vertical transmission of human papillomavirus from infected mothers to their newborn babies and persistence of the virus in childhood. Am J Obstet Gynecol 1996, 174:694-699. A careful long term follow-up study of women with genital HPV infections, which shows a correlation between genital HPV16/18 infection in the mother and oral HPV16/18 infection in the child several years after birth, providing good evidence for oral infection with high-risk viruses and vertical transmission.
27. Leimolavirtanen R, Syrjanen S: Failure to detect human papillomavirus DNA in the oral mucosa of postmenopausal women. Clin Infect Dis 1996, 22:593-594.
28. Franco EL, Villa LL, Ruiz A, Costa MC: Transmission of cervical human papillomavirus infection by sexual activity: differences between low and high oncogenic risk types. J Infect Dis 1995, 172:756-763.
29. Bell JA, Sundberg JP, Ghim SJ, Newsome J, Jenson AB, Schlegel R: A formalin inactivated vaccine protects against mucosal papillomavirus infection: a canine model. Pathobiology 1994, 62:194-198.
30. Suzich JA, Ghim SJ, Palmer Hill FJ, White WI, Tamura JK, Bell JA, Newsome JA, Jenson AB, Schlegel R: Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995, 92:11553-11557. This study shows that immunization with L1 alone completely protects against challenge with the mucosal virus COPV. It also shows that L1 must be in the native conformation for protection.
31. Jansen KU, Rosolowsky M, Schultz LD, Markus HZ, Cook JC, Donnelly JJ, Martinez D, Ellis RW, Shaw AR: Vaccination with yeast expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine 1995, 13:1509-1514.
32. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C, Orth G, Schiller JT, Lowey DR: Immunization with virus-like particles from cotton tail rabbit papillomavirus (CRPV) can protect against experimentally CRPV infection. J Virol 1995, 69:3959-3963.
33. Christensen ND, Kreider JW, Kan NC, DiAngelo SL: The open reading frame L2 of cottontail rabbit papillomavirus contains antibody inducing neutralizing epitopes. Virology 1991, 181:572-579.
34. Christensen ND, Reed CA, Cladel NM, Han R, Kreider JW: Immunization with viruslike particles induces long term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 1996, 70:960-965.
35. Donnelly JJ, Martinez D, Jansen KU, Ellis RW, Montgomery DL, Liu MA: Protection against papillomavirus with a polynucleotide vaccine. J Infect Dis 1996, 173:314-320. An important paper which demonstrates the efficacy of a DNA vaccine encoding the L1 of CRPV.
36. Kirnbauer R, Chandrachud LM, O'Neill BW, Wagner ER, Grindlay GJ, Armstrong AA, McGarvie GM, Schiller JT, Lowy DR, Campo MS: Virus-like particles of bovine papilloma virus type 4 in prophylactic and therapeutic immunization. Virology 1996, 219:37-44.
37. Chandrachud LM, Grindlay GJ, McGarvie GM, O'Neill BW, Wagner ER, Jarrett WFH, Campo MS: Vaccination of cattle with the N-terminus of L2 is necessary and sufficient for preventing infection by bovine papillomavirus-4. Virology 1995, 211:204-208.
38. Gaukroger JM, Chandrachud LM, O'Neil BW, Grindlay GJ, Knowles G, Campo MS: Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus-neutralizing antibodies. J Gen Virol 1996, 77:1577-1583.
39. Ghim SJ, Young R, Jenson AB: Antigenicity of bovine papillomavirus type 1 (BPV-1) L1 virus-like particles compared with that of intact BPV-1 virions. J Gen Virol 1996, 77:183-188.
40. Christensen ND, Kreider JW, Cladel NM, Patrick SD, Welsh PA: Monoclonal antibody mediated neutralization of infectious human papillomavirus type 11. J Virol 1990, 64:5678-5681.
41. Smith LH, Foster C, Hitchcock ME, Leiserowitz GS, Hall K, Isseroff R, Christensen ND, Kreider JW: Titration of HPV 11 infectivity and antibody neutralization can be measured in vitro. J Invest Dermatol 1995, 105:438-444.
42. Cheng G, Icenogle JP, Kirnbauer R, Hubbert NL, St Louis ME, Han C, Svare EI, Kjaer SK, Lowy DR, Schiller JT: Divergent human papillomavirus type 16 variants are serologically cross reactive. J Infect Dis 1995, 172:1584-1587.
43. Roden RB, Hubbert NL, Kirnbauer R, Christensen ND, Lowy DR, Schiller JT: Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol 1996, 70:3298-3301.
44. Roden RBS, Greenstone HL, Kirnbauer R, Booy FP, Jessie J, Lowy DR, Schiller JT: In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol 1996, 70:5875-5883. An important study taking a high tech approach to the problem of neutralization assays for HPVs in the absence of sources of native virus by generating pseudovirions with HPV coat proteins encapsidating BPV genomes.
45. Yamada T, Wheeler CM, Halpern AL, Stewart AC, Hildesheim A, Jenison SA: Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. J Virol 1995, 69:7743-7753.
46. Icenogle JP, Clancy KA, Lin SY: Sequence variation in the capsid protein genes of human papillomavirus type 16 and type 31. Immunol 1995, 214:664-669.
47. Xi LF, Demers GW, Koutsky LA, Kiviat NB, Kuypers J, Watts DH, Holmes KK, Galloway DA: Analysis of human papillomavirus type 16 variants indicates establishment of persistent infection. J Infect Dis 1995, 172:747-755.
48. Fruchter RG, Maiman M, Sedlis A, Bartley L, Arrastia CD: Multiple recurrence of cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Obstet Gynecol 1996, 87:338-344.
49. Fennema JS, Van Ameijden EJ, Coutinho RA, Van Den Hoek AA: HIV, sexually transmitted diseases and gynaecologic disorders in women: increased risk for genital herpes and warts among HIV infected prostitutes in Amsterdam. AIDS 1995, 9:1071-1078.
50. Chirgwin KD, Feldman J, Augenbraun M, Landesman S, Minkoff H: Incidence of venereal warts in human immunodeficiency virus infected and uninfected women. J Infect Dis 1995, 172:235-238.
51. de Gruijl TD, Bontkes HJ, Stukart MJ, Walboomers JMM, Remmink A, Verheijen RHM, Helmerhorst TJM, Meijer CJLM, Scheper R: T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with persistent viral infection. J Gen Virol 1996, 77:2183-2191.
52. Shepherd PS, Rowe AJ, Cridland JC, Coletart T, Wilson P, Luxton JC: Proliferative T cell responses to human papillomavirus type 16 L1 peptides in patients with cervical dysplasia. J Gen Virol 1996, 77:593-602.
53. McGarvie GM, Grindlay GJ, Chandrachud LM, O'Neill BW, Jarrett WFH, Campo MS: T-cell responses to BPV-E7 during infection and mapping of T-cell epitopes. Virology 1995, 206: 504-510.
54. Selvakumar R, Ahmed R, Wettstein FO: Tumor regression is associated with a specific immune response to the E2 protein of cotton tail rabbit papillomavirus. Virology 1995, 208:298-302. An important study in the rabbit model which demonstrates a specific T cell lymphoproliferative response to an early protein E2 when CRPV-induced papillomas regress.
55. Selvakumar R, Borenstein LA, Lin Y-L, Ahmed R, Wettstein FO: Immunization with nonstructural proteins E1 and E2 of cotton tail rabbit papillomavirus stimulates regression of virus-induced papillomas. J Virol 1995, 69:602-605. A continuation of [54], in which therapeutic immunization with the early proteins E1 and E2 is shown to enhance the regression of CRPV-induced papillomas.
56. Routes JM, Ryan S: Oncogenicity of human papillomavirus or adenovirus transformed cells correlates with resistance to lysis by natural killer cells. J Virol 1995, 69:7639-7647.
57. Tarpey I, Stacey S, Hickling J, Birley HD, Renton A, Mclndoe A, Davies DH: Human cytotoxic T lymphocytes stimulated by endogenously processed human papillomavirus type 11 E7 recognise a peptide containing a HLA A2 (A0201) motif. Immunology 1994, 81:222-227.
58. Ressing ME, Van Driel WJ, Celis E, Sette A, Brandt MP, Hartman M, Anholts JD, Schreuder GM, Ter Harmsel WB, Fleuren GJ et al.: Occasional memory cytotoxic T cell responses of patients with human papillomavirus type 16 positive cervical lesions against a human leukocyte antigen A 0201 restricted E7 encoded epitope. Cancer Res 1996, 56:582-588.
59. Evans CA, Bauer S, Grubert T, Brucker C, Baur S, Heeg K, Wagner H, Lipford GB: HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions. Cancer Immunol Immunother 1996, 42:151-160.
60. Kast WM, Brandt RM, Sidney J, Drijfhout JW, Kubo RT, Grey HM, Melief CJ, Sette A: Role of HLA A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol 1994, 152:3904-3912.
61. Ressing ME, Sette A, Brandt RM, Ruppert J, Wentworth PA, Hartman M, Oseroff C, Grey HM, Melief CJ, Kast WM: Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA A0201 binding peptides. J Immunol 1995, 154:5934-5943.
62. Lipford GB, Bauer S, Wagner H, Heeg K: Peptide engineering allows cytotoxic T cell vaccination against human papilloma virus tumour antigen, E6. Immunology 1995, 84:298-303.
63. Ossevoort MA, Feltkamp MC, Van Veen KJ, Melief CJ, Kast WM: Dendritic cells as carriers for a cytotoxic T lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16 induced tumor. J Immunother Emphasis Tumor Immunol 1995, 18:86-94.
64. Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GWG, Westmoreland D, Evans AS, Adams M, Stacey SN, Boursnell MEG et al.: A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996, 347:1523-1527. A very significant phase I/II trial with a live recombinant viral vaccine, which establishes safety and immunogenicity of the vaccine in patients with advanced cervical cancer.